RJT
HQL

Raymond James Trust’s abrdn Life Sciences Investors HQL Stock Holding History

Raymond James Trust’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,907
Closed -$175K – 1179
2023
Q2 		$175K Hold
12,907
– – 0.01% 1129
2023
Q1 		$180K Buy
12,907
+750
+6% +$10.7K 0.01% 1083
2022
Q4 		$173K Hold
12,157
– – 0.01% 1067
2022
Q3 		$166K Buy
+12,157
New +$182K 0.01% 1009

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
CA
Cornerstone Advisors Asheville, North Carolina $2.72B AUM 22.17% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return

Raymond James Trust's HQL Position: Q3 2023 in Review

Raymond James Trust sold out of abrdn Life Sciences Investors (HQL) in Q3 2023, closing a stake of 12,907 shares — an estimated $175K sold.

Raymond James Trust first reported a position in HQL in Q3 2022 and held it in 4 quarters. The position peaked at $180K in Q1 2023. 80 funds tracked by Wall St. Rank hold HQL as of Q3 2023.

  • Raymond James Trust reported no remaining abrdn Life Sciences Investors position as of Q3 2023 after selling out during the quarter.
  • Raymond James Trust sold 12,907 abrdn Life Sciences Investors shares in Q3 2023, an estimated $175K.
  • Raymond James Trust first reported a position in abrdn Life Sciences Investors in Q3 2022 and held it in 4 quarters.
  • Raymond James Trust's abrdn Life Sciences Investors position peaked at $180K in Q1 2023.
  • 80 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2023.

Based on Raymond James Trust's 13F filing for Q3 2023, filed 14 Nov 2023.